A Case of Atypical Unilateral Optic Neuritis Following BNT162b2 mRNA COVID-19 Vaccination

Shuntaro Motegi, Takayuki Kanda and Masaru Takeuchi *

Department of Ophthalmology, National Defense Medical College, 3-2 Namiki, Tokorozawa 359-8513, Japan

* Correspondence: masatake@ndmc.ac.jp; Tel.: +81-42-995-1211; Fax: +81-42-995-5332

Abstract: Background: We report a case of atypical unilateral optic neuritis after receiving the BNT162b2 mRNA-based COVID-19 vaccine. Case Presentation: An 86-year-old man complained of blurred vision and decreased visual acuity in his right eye 8 days after receiving the second BNT162b2 mRNA-based COVID-19 vaccine and was referred to our hospital. He also had pain with eye movement. Best corrected visual acuity (BCVA) in the right eye was 20/200 and critical flicker frequency dropped to 16 Hz. Relative afferent pupillary defect was positive and central scotomas were observed on visual field analysis. Fundus examination and SD-OCT revealed optic disc swelling and apparent thickening of the retinal nerve fiber layer around the optic disc in the right eye. Although either an increase in CRP or ESR on laboratory tests, demyelinating lesion on MRI, or positive of anti-MOG antibodies or anti-AQP4 antibodies were not observed, fluorescein angiography presented only hyperfluorescence of the optic disc in the right eye, but there were no findings such as papillary deficiency and choroidal delay that would suggest ischemic optic neuropathy. We diagnosed atypical optic neuritis developed after the SARS-CoV-2 mRNA-based vaccination and initiated oral corticosteroid therapy. One month later, the optic disc swelling disappeared and BCVA improved to 20/100; however, the central scotoma remained and no further improvement in visual function OD was obtained. Conclusions: An atypical acute idiopathic optic neuritis can occur after receiving the second vaccination with BNT162b2, which may present a limited response to corticosteroid therapy.

Keywords: COVID-19; optic neuritis; mRNA vaccine; vaccination

1. Background

Coronavirus disease 2019 (COVID-19) remains rampant worldwide, with the development of vaccines against the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) progressing rapidly with an urgent demand. Several vaccines have been approved for emergency use for the prevention of COVID-19, though critical adverse events of the vaccines have not been fully investigated.

Multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) after COVID-19 vaccination have been reported [1–6], while a complication of optic neuritis (ON) is also known [7–10]. Although idiopathic ON after COVID-19 vaccination is also reported [11–15], those visual prognoses are generally favorable. We report a case of atypical unilateral ON after receiving the BNT162b2 mRNA-based COVID-19 vaccine, in which the recovery of visual functions was restricted despite corticosteroid therapy.

2. Case Presentation

An 86-year-old man who complained of blurred vision and decreased visual acuity in the right eye visited a local eye clinic. This patient had received the second dose of the BNT162b2 mRNA-based COVID-19 vaccine 8 days before the onset of his ocular symptoms. Since the patient was also aware of pain with eye movement, he was referred to our hospital on suspicion of optic neuritis. He had a history of arrhythmia, but had no abnormalities...
such as flu-like symptoms before vaccination. At presentation, the best-corrected visual acuity (BCVA) was 20/200 in the right eye (OD) and 20/20 in the left eye (OS), with intraocular pressure (IOP) 14 mmHg OD and 15 mmHg OS. Critical flicker frequency (CFF) was 16 Hz OD and 47 Hz OS. Relative afferent pupillary defect (RAPD) OD was observed and fundus examination revealed optic disc swelling OD (Figure 1A,B). Fluorescein angiography (FA) OD showed only hyperfluorescence of the optic disc (Figure 1C,D), with no findings such as papillary filling deficiency and choroidal delay that would suggest ischemic optic neuropathy. Humphrey’s visual field analysis (HFA) and spectral domain optical coherence tomography (SD-OCT) OD revealed central scotomas (Figure 1E,F) and apparent thickening of the retinal nerve fiber layer (RNFL) around the optic disc (Figure 2). Alternatively, laboratory tests including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) indicated no abnormal values. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies or anti-aquaporin 4 (AQP4) antibodies were also examined by commercial-based cell-based assays (CBAs) using live transfected cells, but were negative. Intracranial magnetic resonance imaging (MRI) indicated neither a contrast-enhanced effect of gadolinium on the optic nerve nor abnormalities such as demyelinating lesions. Non-arteritic anterior ischemic optic neuropathy (NA-AION) was suspected based on the patient’s age and his medical history of arrhythmia; however, FA findings and HFA results were consistent with acute idiopathic optic neuritis OD, contrary to NA-AION. Since the patient had received the second BNT162b2 mRNA-based COVID-19 vaccine 8 days before the onset of ocular symptoms OD, a side effect of the COVID-19 vaccine was suspected to be the possible cause. Considering the patient’s advanced age, methylprednisolone pulse administration was avoided and oral corticosteroid therapy was initiated from 0.6 mg/kg. One month later, although the optic disc swelling OD had gradually resolved (Figure 3A,B) and BCVA OD had improved to 20/100, the central scotoma remained (Figure 3C,D) and no further improvement in visual function OD was obtained. There was no inflammation in the left eye during these events.

Figure 1. (A,B) color fundus photographs of the right eye (A) and left eye (B) 8 days after receiving the second COVID-19 vaccination. (C,D) fluorescein angiography findings in the right eye (C) and left eye (D) at the late stage. (E,F) Humphrey’s visual field analysis of the right eye (E) and left eye (F).
Figure 1. (A,B) color fundus photographs of the right eye (A) and left eye (B) 8 days after receiving the second COVID-19 vaccination. (C,D) fluorescein angiography findings in the right eye (C) and left eye (D) at the late stage. (E,F) Humphrey’s visual field analysis of the right eye (E) and left eye (F).

Figure 2. Retinal nerve fiber layer thickness around the optic nerve head of the right eye (OD) and left eye (OS) measured by spectral domain optical coherence tomography.
Figure 3. (A,B) color fundus photographs of the right eye (A) and left eye (B) 1 month after receiving the second COVID-19 vaccination. (C,D) Humphrey’s visual field analysis of the right eye (C) and left eye (D).

3. Discussion

Optic neuropathy is suspected as one of adverse events of the COVID-19 vaccine, which includes ON associated with or without demyelinating CNS diseases [7–16], NA-AION [17–24], and NMOSD [8,9]. Lotan et al. reviewed 14 case reports and 2 case series by electronic searches of the published literature regarding neuro-ophthalmological complications of COVID-19 vaccines and reported that optic neuritis was the most common, occurring in 61 of 76 cases (80.3%) [25]. We reviewed the previous reports of newly onset optic neuropathy after receiving COVID-19 vaccines and compared clinical manifestations, management, and outcomes in Table 1. The onset after receiving COVID-19 vaccines ranged from 1 day to 3 weeks, in which 7 of all 26 cases (26.9%) were associated with relapsing-remitting multiple sclerosis (RRMS) or NMOSD, with 10 cases (38.5%) idiopathic ON. High-dose pulse steroid therapy was useful in most cases and their visual prognosis was favorable. Although visual acuity was not fully recovered in 3 cases [13], those were not as high as in this case. NA-AION was also reported in 8 cases (30.8%), with ON suspected in some cases.
### Table 1. Published cases reports of optic neuropathy after receiving COVID-19 vaccines.

| Author (Year) | Age (Sex) | Medical History | Clinical Presentation | Diagnosis | Vaccine | Time between Vaccination and Symptoms | Treatment | Final Visual Acuity |
|---------------|-----------|-----------------|-----------------------|-----------|---------|---------------------------------------|-----------|---------------------|
| Ayman G Elnahry (2021) [11] | 69 (female) | None | Bilateral vision loss | Bilateral optic neuritis | mRNA (Pfizer-BioNTech) 2nd dose | 16 days | 1000 mg/day intravenous methylprednisolone (IVMP) for 5 days, | Stable |
|  | 32 (female) | None | Blurred vision OS | Optic neuritis OS | Viral vector (Oxford-AstraZeneca) 1st dose | 5 days | 1000 mg/day IVMP for 5 days | 20/20 |
| Henrique M. Leber (2021) [16] | 32 (female) | None | Vision loss and pain OS | Bilateral optic neuritis and thyroiditis Non-arteritic anterior ischemic optic neuropathy (NA-AION) OD | Inactivated (Sinovac) 2nd dose | 12 h | 1000 mg/day IVMP for 5 days | 20/20 OD 20/25 OS |
| Rika Tsukii (2021) [17] | 55 (female) | None | Visual field disturbance OD | Optic neuritis (NA-AION) OD | mRNA (Pfizer-BioNTech) 1st dose | 7 days | No treatment | 20/20 |
| Valentina Arnao (2022) [14] | Middle-age (female) | None | Bilateral blurred vision and pain | Bilateral optic neuritis | Viral vector (Oxford-AstraZeneca) 1st dose | 14 days | 1000 mg/day IVMP for 5 days | Recovered |
| Jiajun Wang (2022) [12] | 21 (female) | None | Blurred vision OD with ocular rotation pain | Optic neuritis OD | Inactivated (Sinopharm) 2nd dose | 3 weeks | 800 mg/day IVMP for 5 days | 20/20 |
| Madhurima Roy (2022) [15] | 27 (female) | None | Progressive blurring of vision OS Painless gradual diminution of vision OS | Optic neuritis OD | Viral vector (Covishield) 1st dose | 9 days | 1000 mg/day IVMP for 5 days | 20/40 |
|  | 48 (female) | None | Blurring vision in both eyes | Optic neuritis OS | Viral vector (Covishield) 2nd dose | 5 days | 1000 mg/day IVMP for 5 days | 20/30 |
|  | 40 (male) | None | Blurring vision in both eyes | Bilateral optic neuritis New onset relapsing-remitting multiple sclerosis (RRMS) | Viral vector (Covishield) 1st dose | 12 days | Steroid therapy | 20/30 OD 20/40 OS |
| Mahsa Khayat-Khoei (2022) [7] | 26 (female) | None | Blurred vision and pain OD | mRNAs (Moderna) 2nd dose | Viral vector (Covishield) 1st dose | 14 days | 1000 mg/day IVMP for 5 days | - |
|  | 64 (male) | RRMS | Vision changes and pain OD | Multiple sclerosis (MS) exacerbation | mRNA (Pfizer-BioNTech) 2nd dose | 1 day | 1000 mg/day IVMP for 5 days | - |
|  | 33 (male) | none | Blurred vision OS | New onset RRMS | mRNA (Pfizer-BioNTech) 2nd dose | 1 day | 1000 mg/day IVMP for 5 days | - |
|  | 48 (female) | Clinically isolated demyelinating syndrome (CIS) | Pain OD, Lhermitte’s, balance/gait | Conversion from CIS to RRMS | mRNA (Pfizer-BioNTech) 1st dose | 15 days | 1000 mg/day IVMP for 5 days | - |
| Christian Garcia-Estrada (2022) [15] | 19 (female) | None | Vision loss and pain OS | Optic neuritis OS | Viral vector (Janssen) 1st dose | 1 week | 1000 mg/day IVMP for 5 days | 20/20 |
| Author (Year)          | Age (Sex) | Medical History                  | Clinical Presentation                                      | Diagnosis                                                                 | Vaccine                                      | Time between Vaccination and Symptoms | Treatment                          | Final Visual Acuity |
|-----------------------|-----------|----------------------------------|------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------|---------------------------------------|--------------------------------------|---------------------|
| Yelda Yıldız Tascı (2022) [8] | 32 (male) | Graves' disease                   | Ocular pain and blurred vision OD                          | Neuromyelitis optica spectrum disorders (NMOSD) OD                       | Inactivated (Sinovac) 1st dose               | 14 days                              | 1000 mg/day IVMP for 5 days             | 20/20               |
| Sai A Nagaratnam (2022) [10] | 36 (female) | None                             | Bilateral vision loss and subjective color desaturation, painful eye movements and fatigue | Viral vector (Oxford–AstraZeneca ChAdOx1) 1st dose                       | mRNA (Pfizer-BioNTech) 2nd dose             | 14 days                              | 1000 mg/day IVMP for 3 days             | 20/16 OD 20/20 OS |
| Bader Shirah (2022) [9] | 31 (female) | Systemic lupus erythematosus (SLE) | Painful eye movements and blurred vision OD                | NA-AION OS                                                              | mRNA (Pfizer-BioNTech) 2nd dose             | 14 days                              | Oral prednisolone 60 mg/day             | 20/80               |
| Wen-Yun Lin (2022) [18] | 61 (female) | Hypertension and hyperlipidemia   | Blurred vision OS                                         | NA-AION OS                                                              | mRNA (Pfizer-BioNTech) 2nd dose             | 7 days                                | Oral prednisone over 1 month            | 20/400              |
| Abdelrahman Elhusseiny (2022) [19] | 51 (male) | None                             | Vision loss OS                                            | NA-AION OS                                                              | mRNA (Pfizer-BioNTech) 2nd dose             | 1 day                                 | Oral prednisone 750 mg/day              | 20/20 OD 20/40 OS |
| Sonia Valero Franco (2022) [20] | 53 (male) | None                             | Bilateral vision loss                                     | Suspected bilateral NA-AION                                              | mRNA (Pfizer-BioNTech) 1st dose OD mRNA (Pfizer-BioNTech) 2nd dose OS | 7 days                                | Acetazolamide 750 mg/day               | 20/20 OD 20/40 OS |
| 65 (male) | Arterial hypertension | Blurred vision OD                | Suspected NA-AION OD                                       | NA-AION OD                                                              | mRNA (Pfizer-BioNTech) 1st dose mRNA (Pfizer-BioNTech) 2nd dose          | 12 days                               | No treatment                          | 20/200              |
| Snejzana Murgova (2022) [21] | 45 (male) | Arterial hypertension            | Visual disturbance OD                                      | NA-AION OD                                                              | mRNA (Pfizer-BioNTech) 1st dose mRNA (Pfizer-BioNTech) 2nd dose          | 10 days                               | Vasodilators and anti-platelet therapy | 20/20               |
| Seung Ah Chung (2022) [22] | 65 (female) | None                             | Sudden inferior visual field loss OD                      | NA-AION OD                                                              | mRNA (Pfizer-BioNTech) 1st dose mRNA (Pfizer-BioNTech) 2nd dose          | 15 days                               | 1000 mg/day IVMP for 3 days             | 20/200              |
| Ilay Caliskan (2022) [23] | 43 (female) | None                             | Blurred vision and movement-associated pain OD            | NMOSD OD                                                                | mRNA (Pfizer-BioNTech) 2nd dose            | 1 day                                 | IVMP and plasma exchange               | -                  |
| Srinivasan Sanjay (2022) [24] | 50s (Female) | Non-arteritic anterior ischaemic optic neuropathy (NA-AION) OD | Vision loss OS                                            | NA-AION OS                                                              | mRNA (Pfizer-BioNTech) 2nd dose            | 4 days                                | Oral aspirin 75 mg for 1 month          | 20/20               |
Clinically, it is often challenging to differentiate ON from NA-AION, with the diagnosis usually based on the patient’s background, clinical findings, and multimodal images. In this case, NA-AION OD was primarily suspected based on the medical history of arrhythmia, the patient’s age, negative result for anti-MOG or anti-AQP4 antibodies, no elevation of ESR or CRP, and no associated neurological signs or abnormalities on an intracranial MRI. However, FA presented only hyperfluorescence of the optic disc, without papillary filling deficiency or choroidal delay suggesting AION was negative. In addition, visual field test results provide the critical clue of the diagnosis. It is well known that central scotomas are highly characteristic of ON, while an inferior altitudinal defect along the horizontal meridian, particularly in the nasal periphery, is characteristic of AION [26]. Although a worse visual outcome in this case is also differentiating features of NA-AION, eye movement pain, FA findings, and central scotomas without the horizontal meridian led us to diagnose acute ON rather than NA-AION.

Hypotheses indicating a causal relationship between COVID-19 vaccination and ON are yet to be proved, but the close temporal association between symptom onset and vaccination strongly supports that possibility. BNT162b2 is a nucleoside-modified mRNA vaccine, which is translated into the SARS-CoV-2 spike protein by the host’s ribosomes, followed by antigen processing and presentation to local immune cells for subsequent neutralizing antibody production and T-cell-mediated immune response [27]. Since there have also been several reports regarding optic neuritis developed after SARS-CoV-2 infection, we speculate that adverse events after receiving the COVID-19 vaccine are probably attributed to the adaptive immune response evoked by the vaccination, and/or the spike protein itself.

The autoimmune mechanism evoked by molecular mimicry of viral proteins and the immunological involvement of adjuvants have been suggested to underlie the development of ON following COVID-19 vaccination [7,28]. Visual prognosis of ON associated with RRMS or idiopathic ON with autoimmune nature is generally favorable by high-dose pulse steroid therapy. The reasons for the inadequate recovery of visual function in this case are speculated to be the avoidance of methylprednisolone pulse administration due to the patient’s advanced age and the impairment of tissue repair associated with aging.

In conclusion, we encountered a case of unilateral atypical ON occurring after the second BNT162b2 mRNA-based COVID-19 vaccination. Warnings should be given to ophthalmologists and physicians about the risk of atypical optic neuritis after COVID-19 vaccination.

**Author Contributions:** Conception, T.K. and M.T.; Design, M.T.; Acquisition, S.M. and T.K.; Analysis, S.M. and T.K.; Data interpretation, S.M., T.K., and M.T.; Writing—original draft preparation, S.M. and M.T.; Writing—review and editing, S.M. and M.T. All authors have read and agreed to the published version of the manuscript. All authors have agreed to be both personally accountable for their own contributions and ensure that questions related to the accuracy or integrity of any part of the manuscript are answered.

**Funding:** The authors received no specific funding for this work.

**Institutional Review Board Statement:** Ethics approval was not applicable. The authors declare that they adhered to the CARE guidelines/methodology.

**Informed Consent Statement:** Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors thank Eiko Machida, Kiyoko Yamada, Tomomi Nakamura, and Saeko Kanno for their contribution to the present report.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Chen, S.; Fan, X.R.; He, S.; Zhang, J.W.; Li, S.J. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. *Neuror Sci* 2021, 42, 3537–3539. [CrossRef] [PubMed]

2. Ozgen Kenangil, G.; Ari, B.C.; Guler, C.; Demir, M.K. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine. *Acta Neurol. Belg.* 2021, 121, 1089–1091. [CrossRef] [PubMed]

3. Roman, G.C.; Gracia, F.; Torres, A.; Palacios, A.; Gracia, K.; Harris, D. Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). *Front. Immunol.* 2021, 12, 653786. [CrossRef] [PubMed]

4. Pagankopf, C.; Sündmeyer, M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. *J. Neuroimmunol.* 2021, 358, 577606. [CrossRef]

5. Ismail, I.I.; Salama, S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. *J. Neuroimmunol.* 2022, 362, 577765. [CrossRef]

6. Badrawi, N.; Kumar, N.; Albastaki, U. Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. *Radiol. Case Rep.* 2021, 16, 3864–3867. [CrossRef]

7. Khayat-Khoei, M.; Bhattacharyya, S.; Katz, J.; Harrison, D.; Tauhid, S.; Bruso, P.; Houtchens, M.K.; Edwards, K.R.; Bakshi, R. COVID-19 mRNA vaccination leading to CNS inflammation: A case series. *J. Neurol.* 2022, 269, 1093–1106. [CrossRef]

8. Yildiz Tasci, Y.; Nalcacoglu, P.; Gumusyayla, S.; Vural, G.; Toklu, Y.; Yesilirmak, N. Aquaporin-4 protein antibody-associated optic neuritis related to neuroendocrine tumor after receiving an inactive COVID-19 vaccine. *Indian J. Ophthalmol.* 2022, 70, 1828–1831. [CrossRef]

9. Shirah, B.; Mulla, I.; Aladdin, Y. Optic Neuritis Following the BNT162b2 mRNA COVID-19 Vaccine in a Patient with Systemic Lupus Erythematosus Uncovering the Diagnosis of Neuromyelitis Optica Spectrum Disorders. *Ocul. Immunol. Inflamm.* 2022, 18, 1–3. [CrossRef]

10. Nagaratnam, S.A.; Ferdi, A.C.; Leaney, J.; Lee, R.L.K.; Hwang, Y.T.; Heard, R. Acute disseminated encephalomyelitis with bilateral optic neuritis following ChAdOx1 COVID-19 vaccination. *BMC Neurol.* 2022, 22, 54. [CrossRef]

11. Elharny, A.G.; Asal, Z.B.; Shaikh, N.; Dennett, K.; Abd Elmohsen, M.N.; Elharny, G.A.; Shehab, A.; Vytopil, M.; Ghaffari, L.; Athappilly, G.K.; et al. Optic neuropathy after COVID-19 vaccination: A report of two cases. *Int. J. Neurosci.* 2021, 1–7. [CrossRef] [PubMed]

12. Wang, J.; Huang, S.; Yu, Z.; Zhang, S.; Hou, G.; Xu, S. Unilateral optic neuritis after vaccination against the coronavirus disease: Two case reports. *Doc. Ophthalmol.* 2022, 145, 65–70. [CrossRef] [PubMed]

13. Roy, M.; Chandra, A.; Roy, S.; Shrotriya, C. Optic neuritis following COVID-19 vaccination: Coincidence or side-effect?—A case series. *Indian J. Ophthalmol.* 2022, 70, 679–683. [CrossRef] [PubMed]

14. Arnao, V.; Maimone, M.B.; Perini, V.; Giudice, G.L.; Cotton, S. Bilateral optic neuritis after COVID vaccination. *Neuror Sci.* 2022, 43, 2965–2966. [CrossRef]

15. Garcia-Estrada, C.; Gomez-Figueroa, E.; Alban, L.; Arias-Cardenas, A. Optic neuritis after COVID-19 vaccine application. *Clin. Exp. Neuroimmunol.* 2022, 13, 72–74. [CrossRef]

16. Leber, H.M.; Sant’Ana, L.; Konichi da Silva, N.R.; Raio, M.C.; Mazzeo, T.; Endo, C.M.; Nascimento, H.; de Souza, C.E. Acute Thyroiditis and Bilateral Optic Neuritis following SARS-CoV-2 Vaccination with CoronaVac: A Case Report. *Ocul. Immunol. Inflamm.* 2021, 29, 1200–1206. [CrossRef] [PubMed]

17. Tsuki, R.; Kasuya, Y.; Makino, S. Nonarteritic Anterior Ischemic Optic Neuropathy following COVID-19 Vaccination: Sequence or Coincidence. *Case Rep. Ophthalmol. Med.* 2021, 2021, 5126254. [CrossRef] [PubMed]

18. Lin, W.Y.; Wang, J.J.; Lai, C.H. Non-Arteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination: A Case Series. *J. Ophthalmic Inflamm. Infect.* 2022, 12, e935095. [CrossRef] [PubMed]

19. Elhusseiny, A.M.; Sanders, R.N.; Siddiqui, M.Z.; Sallam, A.B. Non-arteritic Anterior Ischemic Optic Neuropathy with Macular Star following COVID-19 Vaccination. *Ocul. Immunol. Inflamm.* 2021, 2, 1–4. [CrossRef] [PubMed]

20. Valsero Franco, S.; Fonollola, A. Ischemic Optic Neuropathy After Administration of a SARS-CoV-2 Vaccine: A Report of 2 Cases. *Ann. J. Case Rep.* 2022, 23, e935095. [CrossRef]

21. Murgova, S.; Balchev, G. Ophthalmic manifestation after SARS-CoV-2 vaccination: A case series. *J. Ophthalmic Inflamm. Infect.* 2022, 12, 20. [CrossRef] [PubMed]

22. Chung, S.A.; Yeo, S.; Sohn, S.Y. Nonarteritic Anterior Ischemic Optic Neuropathy Following COVID-19 Vaccination: A Case Report. *Korean J. Ophthalmol.* 2022, 36, 168–170. [CrossRef]

23. Caliskan, I.; Bulus, E.; Afsar, N.; Altintas, A. A Case With New-Onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination. *Neurologist* 2022, 27, 147–150. [CrossRef] [PubMed]

24. Sanjay, S.; Acharya, J.; Rawoof, A.; Shetty, R. Non-arteritic anterior ischaemic optic neuropathy (NA-AION) and COVID-19 vaccination. *BMJ Case Rep. CP* 2022, 15, e248415. [CrossRef] [PubMed]

25. Lotan, I.; Lydston, M.; Levy, M. Neuro-Ophtalmological Complications of the COVID-19 Vaccines: A Systematic Review. *J. Neuroophthalmol.* 2022, 42, 154–162. [CrossRef]

26. Gerling, J.; Meyer, J.H.; Kommerrell, G. Visual field defects in optic neuritis and anterior ischemic optic neuropathy: Distinctive features. *Graefes Arch. Clin. Exp. Ophthalmol.* 1998, 236, 188–192. [CrossRef]
27. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* 2020, 383, 2603–2615. [CrossRef]

28. Karussis, D.; Petrou, P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. *Autoimmun. Rev.* 2014, 13, 215–224. [CrossRef]